Where is Xontogeny's headquarters located?

Xontogeny's headquarters is located in Boston (United States).

How big is Xontogeny's investment team?

Xontogeny has a team of 11, including 4 partners.

How many companies has Xontogeny invested in?

Xontogeny has invested in 28 companies, including Forge Biologics & Cargo Therapeutics.

Which companies has Xontogeny invested in lately?

Zucara Therapeutics & CereVasc are the latest investments by Xontogeny.

How many exits has Xontogeny been involved in?

Xontogeny's portfolio has seen 3 IPOs and 7 acquisitions.

Xontogeny - 2026 Investor Profile, Portfolio, Team & Investment Trends

Xontogeny, an accelerator and incubator program founded in 2016, is based in Boston, United States. With a presence in 4 countries, it has supported around 28 startups in sectors like Life Sciences, High Tech. As of Jul 2026, Xontogeny has witnessed 10 portfolio exits. Most notable companies in its portfolio include Forge Biologics, Cargo Therapeutics and Apogee Therapeutics. The program is backed by a team of 11 people who primarily support Series A startups based in United States. Its latest investment was a $20M Series B round in Zucara Therapeutics on Nov 12, 2024 along with Sanofi.

Key Metrics

Founded Year

2016

Location

Boston, United States

Portfolio Companies

Forge Biologics, Cargo Therapeutics & 26 more

Sectors of Investment

Life Sciences, High Tech & 2 more

Stages of Investment

Series A, Seed & 3 more

Locations of Investment

United States, Canada & 2 more

View Xontogeny's full profile

Xontogeny has a portfolio of 28 companies. Their most notable investments are in Quellis Biosciences and Surf Bio.Their portfolio spans across United States, Canada, China and 1 more locations. They have invested in Life Sciences, High Tech, Consumer and 1 other sectors, across stages such as Series A, Seed and 3 more. Here is the list of top investments by Xontogeny:

1. Forge Biologics

Developer of gene therapeutic solutions for treating multiple diseases. It has developed gene therapies that aim to help patients suffering from rare diseases. Products include FBX-101 which helps to treat infantile Krabbe diseases, FBX-201 for rare and monogenic diseases, and FBX-301 for rare & cancer diseases.

Key facts about Forge Biologics

Founded Year: 2020
Location: Columbus (United States)
Stage: Acquired
Total Funding till date: $330M
Employee Count: 437 as on May 31, 2026
Investors: Perceptive Advisors, Aisling Capital and 7 Others
Latest Funding Round: Series C, Sep 12, 2022, $*****
Highlight: Acquired

2. Cargo Therapeutics

Developer of cell-based therapeutics for cancer treatment. It offers CAR T-cell therapies which include CD22 CAR T, and Multi-Specific CAR T drug candidates for the treatment of hematological malignancies, and solid tumors.

Key facts about Cargo Therapeutics

Founded Year: 2021
Location: San Mateo (United States)
Stage: Acquired
Total Funding till date: $200M
Employee Count: 76 as on Sep 02, 2025
Investors: Janus Henderson Investors, T. Rowe Price and 13 Others
Latest Funding Round: Series A, Feb 09, 2023, $*****
Highlight: Acquired

3. Apogee Therapeutics

Developer of therapeutics for immunological and inflammatory disorders. The company is advancing a pipeline of product candidates, which includes APG777, for the treatment of immunological, inflammatory disorders, and autoimmune disorders.

Key facts about Apogee Therapeutics

Founded Year: 2022
Location: Waltham (United States)
Last Known Valuation: $*****
Stage: Acquired
Total Funding till date: $149M
Employee Count: 313 as on May 31, 2026
Investors: Access Industries, RTW Investments and 5 Others
Latest Funding Round: Series B, Dec 07, 2022, $*****
Highlight: Acquired

4. Astria Therapeutics

Developer of therapeutics for rare diseases. It offers a lead candidate STAR-0215 which is a monoclonal antibody inhibitor of plasma kallikrein for the treatment of hereditary angioedema, and allergic and immunological diseases.

Key facts about Astria Therapeutics

Founded Year: 2008
Location: Boston (United States)
Last Known Valuation: $*****
Stage: Acquired
Total Funding till date: $117M
Employee Count: 54 as on May 31, 2026
Investors: MedImmune Ventures, Perceptive Advisors and 3 Others
Latest Funding Round: Post IPO, Jan 29, 2021, $*****
Highlight: Acquired

5. CereVasc

CereVasc is developing eShunt, a device for the treatment of patients with communicating hydrocephalus (a neurological condition affecting both children and adults). The company is developing a non-invasive solution including a cerebrospinal fluid shunt and catheter-based delivery system.

Key facts about CereVasc

Founded Year: 2015
Location: Auburndale (United States)
Stage: Series C
Total Funding till date: $199M
Investors: Bain Capital Life Sciences, Medtronic and 6 Others
Latest Funding Round: Series C, Jun 04, 2026, $*****
Highlight: Editors' Pick

View the full list of portfolio companies

Xontogeny has invested in 28 companies over the last 9 years, with an average of 3 new investments annually in the last 5 years. Its most recent first time investment was in Zucara Therapeutics and most recent follow-on round was in CereVasc.

Here are Xontogeny's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	0	0	0
2024	3	1	4
2023	4	1	5
2022	4	1	5
2021	6	1	7
2020	3	0	3
2019	0	0	0
2018	0	0	0
2017	2	0	2

View all investments by Xontogeny

Xontogeny has made 11 investments in Series A stage with an average round size of $55.9M, 7 investments in Seed stage with an average round size of $6.59M, 2 investments in Series B stage with an average round size of $89M, 1 investment in Series C stage with an average round size of $189M and 1 investment in Unattributed stage.

Here are Xontogeny's investments by stage:

Stage of entry	No. of Investments
Series A	11
Seed	7
Series B	2
Series C	1
Unattributed	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Consumer and Environment. Notably, it has invested in 27 Enterprise (B2B) companies, 27 Tech companies and 1 Tech hardware company.

Here are Xontogeny's investments by sector:

Sector	No. of Investments
Life Sciences	22
High Tech	2
Sustainability Tech	2
Consumer	1
Environment	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has made most investments in United States (20), followed by Canada where it has made 1 investment.

Here are Xontogeny's investments by geography:

Country	No. of Investments
United States	20
Canada	1
Switzerland	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has not made any investment in 2026 so far.

Here are the most recent investments by Xontogeny:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Nov 12, 2024	Zucara Therapeutics	Canada	Series B	3724	Sanofi
May 13, 2024	CereVasc	United States	Series B	9712	Bain Capital
Apr 24, 2024	Adaptilens	United States	Series A	3393	Pillar VC [+1]
Apr 03, 2024	Neurosterix	Switzerland	Series A	6446	Perceptive Advisors [+1]
Sep 27, 2023	Avalyn Pharma	United States	Series C	7754	Perceptive Advisors [+13]

See more recent investments made by Xontogeny

3 of Xontogeny's portfolio companies have become public. Avalyn Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Apr 2026 at marketcap of $753M and LianBio got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $325M.

Here are Xontogeny's portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Avalyn Pharma	Apr 30, 2026	Sep 27, 2023	Series C	3765
LianBio	Nov 01, 2021	-	-	2043
Solid Biosciences	Jan 26, 2018	-	-	7291

View more details about public companies in Xontogeny's portfolio

7 companies from Xontogeny's portfolio have been acquired. The most recent acquisition was Apogee Therapeutics in Jun 2026 by AbbVie for $*****.

Here are Xontogeny's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Apogee Therapeutics	Jun 22, 2026	-	-	3176
Surf Bio	Jan 28, 2026	Apr 12, 2022	Seed	1268
Astria Therapeutics	Oct 14, 2025	-	-	6295
Cargo Therapeutics	Jul 08, 2025	Feb 09, 2023	Series A	9858
Landos Biopharma	Mar 25, 2024	-	-	5615

View all acquired companies in Xontogeny's portfolio

Xontogeny has a team of 11 members including 4 Partners and 2 Principals located in United States. Xontogeny's team does not sit on the board of any company as of now.

Here is a list of top team members in Xontogeny:

Name	Designation	Location	Board Memberships	Contact Details
Adam Stone	Partner	New York City	-	-
Gianna Hoffman Luca	Partner	San Francisco	-	-
Fred Callori	Partner	Boston	-	-
Joseph Edelman	Partner	New York City	-	-
Takeru Furuya	Principal	Cambridge	-	-
Maggie Clarkeson-Carroll	Principal	New York City	-	-

View team details of Xontogeny

Over the past 9 years, 111 investors have co-invested in Xontogeny's portfolio companies. This includes funds and angels.

Invested before Xontogeny: HHS, F-Prime Capital and 43 others have invested in rounds before Xontogeny. There are 4 companies where HHS has invested before Xontogeny and 1 company where F-Prime Capital has invested before Xontogeny.
Top Co-investors of Xontogeny: 47 investors entered a company along with Xontogeny. These include investors like Perceptive Advisors (4 companies).
Invested after Xontogeny: A total of 19 investors have invested in Xontogeny's portfolio after their investments. Top Investors include Perceptive Advisors (3 companies) and Citadel (2 companies).